| Stanford University - Stanford NMDRC | |
|---|---|
| Logo placeholder | |
| Location | Stanford, CA, USA |
| Type | University Research Center |
| Website | https://med.stanford.edu/nmdrc.html |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers), [FTD](/diseases/ftd), [ALS](/diseases/als) |
| Departments | Department of Neurology |
Stanford University's National Molecular Diagnostics Resource for Neurodegenerative Disease (Stanford NMDRC) is one of the nation's premier research centers for understanding the molecular basis of neurodegenerative diseases[1]. Located in the heart of Silicon Valley, Stanford leverages unique opportunities for interdisciplinary collaboration between basic scientists, clinicians, engineers, and computational biologists.
The Stanford NMDRC integrates cutting-edge molecular biology, systems neuroscience, and clinical research to investigate Alzheimer's disease, frontotemporal dementia, ALS, Parkinson's disease, and related disorders[2]. The center's proximity to technology companies enables innovative collaborations in data science, artificial intelligence, and biomedical engineering.
The NMDRC's molecular diagnostics program represents a cornerstone of Stanford's neurodegenerative disease research:
Stanford has established one of the world's leading FTD research programs:
The ALS program at Stanford benefits from the multidisciplinary stem:
The Stanford Alzheimer's Disease Research Center (ADRC) investigates:
| Condition | Focus | Phase | Status |
|---|---|---|---|
| FTD | Tau antibody | Phase 2 | Recruiting |
| ALS | Antisense therapy | Phase 3 | Active |
| Alzheimer's disease | Anti-amyloid | Phase 3 | Various |
| Parkinson's disease | Gene therapy | Phase 1/2 | Enrolling |
| Researcher | H-index | Focus Areas |
|---|---|---|
| Adam L. Boxer | 95 | FTD, tauopathies, clinical trials |
| Gilbert Y. F. L. Kim | 85 | ALS, motor neuron disease |
| Michael A. G. Greicius | 75 | Alzheimer's disease, neuroimaging |
| Joanne R. L. W. Norton | 70 | FTD, behavioral neurology |
Stanford's location in Silicon Valley enables unique innovation partnerships:
Stanford provides comprehensive training in neurodegenerative research:
Stanford NMDRC priorities include:
Stanford's unique position in Silicon Valley facilitates unprecedented collaborations between neurodegeneration researchers and technology companies. Partnerships with leading AI companies enable development of machine learning algorithms for analyzing neuroimaging data, electronic health records, and genetic datasets[1:1]. These collaborations have produced novel diagnostic tools and predictive models that are being integrated into clinical practice.
The Stanford Neuroscience Health Analytics Program develops data pipelines that integrate clinical, imaging, genetic, and biomarker data from thousands of patients. This multi-modal database supports research on disease progression patterns and treatment response predictors[2:1].
The Stanford NMDRC training program prepares the next generation of neurodegeneration researchers through:
The annual Stanford Neurodegeneration Conference brings together leading scientists from around the world to present latest findings and foster collaborations[3:1].
Stanford maintains active partnerships with pharmaceutical and biotechnology companies to accelerate therapeutic development. These partnerships provide:
Stanford AI Lab. Neuroscience AI Partnerships. 2024. ↩︎ ↩︎
Stanford Health Analytics. Multi-modal Database. 2024. ↩︎ ↩︎
Stanford Conference. Annual Neurodegeneration Meeting. 2024. ↩︎ ↩︎